Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 9% - Should You Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares were down 9% on Friday . The company traded as low as $17.83 and last traded at $17.16. Approximately 654,873 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 1,566,423 shares. The stock had previously closed at $18.85.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup decreased their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Stock Down 11.1%

The business's 50 day moving average is $16.34 and its 200 day moving average is $16.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.15 and a current ratio of 5.15. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -11.97, a price-to-earnings-growth ratio of 19.71 and a beta of 0.93.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the prior year, the business posted ($1.02) EPS. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 25.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after purchasing an additional 2,222,223 shares in the last quarter. Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $38,622,000. Vanguard Group Inc. increased its stake in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after purchasing an additional 1,018,273 shares in the last quarter. Finally, Farallon Capital Management LLC purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $11,821,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.